anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Feminization of health workforce has been globally documented, but it has not been investigated in China. This study aims to analyze changes in the gendered composition of health workforce and explore the trend in different types of health workforce, health organizations and majors within China's health system.
METHODS: The data were collected from China Health Statistical Yearbook from 2002 to 2020. We focused on health professionals including doctors, nurses, and pharmacists in health organizations. Trend analysis was employed to examine the change in the ratio of female health workforce over 18 years. The estimated average annual percent change (AAPC) was estimated, and the reciprocals of variances for the female ratios were used as weights.
RESULTS: In China, health professionals increased from 4.7 million in 2002 to 10.68 million in 2020. Health professionals per 1000 population increased from 3.41 in 2002 to 7.57 in 2020. The ratio of female health professionals significantly increased from 63.85% in 2002 to 72.4% in 2020 (AAPC = 1.04%, 95% CI 0.96-1.11%, P < 0.001). Female doctors and pharmacists increased 4.7 and 7.9 percentage points from 2002 to 2020. Female health workers at township health centers, village clinics, centers for disease control and prevention had higher annual increase rate (AAPC = 1.67%, 2.25% and 1.33%, respectively) than those at hospital (0.70%) and community health center (0.5%). Female doctors in traditional Chinese medicine, dentistry and public health had higher annual increase rate (AAPC = 1.82%, 1.53% and 1.91%, respectively) than female clinical doctor (0.64%).
CONCLUSIONS: More women are participating in the healthcare sector in China. However, socially lower-ranked positions have been feminizing faster, which could be due to the inherent and structural gender norms restricting women's career. More collective and comprehensive system-level actions will be needed to foster a gender-equitable environment for health workforce at all levels.
A 64-year-old female patient was admitted to Beijing Chao-Yang Hospital on February 21, 2023 because of right-sided chest pain for more than 4 years and left-sided chest pain for more than 9 months. She had a past medical history of previous tuberculosis and rheumatoid arthritis. A chest CT in October 2018 revealed multiple pulmonary nodules. A CT-guided biopsy showed no tumors, and adenosine deaminase levels in the pleural effusion were elevated, suggesting a high likelihood of tuberculosis. As a result, anti-tuberculosis treatment was initiated in March 2019. In December 2019, she underwent a right lower lobe resection due to localized hydropneumothorax on the right side. Postoperative pathology unveiled granulomatous inflammation with necrosis. A chest CT in May 2020 showed a significant increase in nodules and cavities. In January 2023, a diagnosis of cryptococcal pneumonia was considered, and she was prescribed oral fluconazole. Finally, the diagnosis of pulmonary rheumatoid nodules was confirmed after a pathological consultation of the postoperative specimen. After one month of treatment with oral prednisone and mycophenolate mofetil, a follow-up chest CT showed improvement. It was recommended that she continue with her current treatment and undergo regular chest CT scans.
The potency Units of JEUVEAU (prabotulinumtoxinA-xvfs) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of JEUVEAU cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method [see Warnings and Precautions (5.2) and Description (11)].

Retreatment of JEUVEAU should be administered no more frequently than every three months. Consideration of the cumulative dose is necessary when treating adult patients with JEUVEAU for glabellar lines if other botulinum toxin products are or have been used to treat other indications approved for those products.

The safe and effective use of JEUVEAU depends upon proper storage of the product, selection of the correct dose, and proper reconstitution and administration techniques. Physicians administering JEUVEAU must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures [see Warnings and Precautions (5.4)].
FIELD: medicine, surgery. SUBSTANCE: one should carry out radical surgical sanitation of purulent-septic focus followed by its adequate draining. One should compensate the volume of circulating blood and general heparinization. One should carry out lymphatic drainage of tissues due to intravenous injection of rheopolyglukin. Extracorporal addition of donor's xenospleen is performed along veno-venous contour. Both patient's subclavicular veins are catheterized. Autoblood is directed into xenosplenic artery. Patient's blood is passed through xenosplenic vascular system in constant magnetic field at induction of 50 mTl for 55-60 min at 30-45 ml/min rate at total volume of 1600 ml, not less. Blood's output is conducted out of xenospleen through its vein. Laser irradiation of blood is carried out with low-intensity laser radiation for 55-60 min, at 0.63 mcm wave length, 1.8-2.0 mW power. When autoblood sampling is stopped, spleendeposited blood is removed with 400.0 ml ozonized Ringer-Locke's solution at 2-3 mg/l ozone concentration. After xenospleen is removed, one should introduce 0.03%- sodium hypochlorite solution at 30-40 drops/min rate and 200.0 ml volume. The present innovation enables to prevent entrance of toxins out of infection focus and remove already entered toxins from circulatory system. EFFECT: higher efficiency of surgical treatment. 4 cl, 2 ex, 1 tbl
BACKGROUND/AIM: We aimed to search the relationship between the preoperative PVI (pleth variability index) and intraoperative respiratory parameters to reveal whether PVI can be used as a prediction tool in bariatric surgery.
MATERIALS AND METHODS: Forty patients undergoing bariatric surgery were included. Noninvasive pleth variability index measured via finger probe before induction of general anesthesia. Following intubation each patient was ventilated in controlled mode. Intraoperative blood pressure, peak airway pressure, end-tidal CO2, SpO2, PEEP, and FiO2 were recorded every 5 min for the first 10 min and then every 10 min until extubation. Steroid and bronchodilator requirements were recorded.
RESULTS: The systolic pressure-PVI, oxygen saturation-PVI relationship was statistically significant (p = 0.03, p = 0.013). A relationship was found between pleth variability index and peak airway pressure (p = 0.002). No correlation was detected between end-tidal CO2 and pleth variability index. The relationship between steroid, bronchodilator use, and PVI was significant (p = 0.05, p = 0.01). A positive correlation between PEEP and PVI was detected at varying time points. A positive correlation was found between FiO2-PVI.
CONCLUSION: A relationship was found between PVI and intraoperative peak airway pressures, oxygen saturation, PEEP, bronchodilatator, and steroid usage. This result may be inspiring to conduct larger studies addressing the issue of predicting intraoperative respiratory problems in bariatric surgeries.
The invention discloses an application of a cellular repressor of E1A stimulated gene (CREG) protein activated by E1A, belonging to the technical field of molecular biological medical treatment. Mainly relates to the medical application of CREG protein in preventing or treating vascular calcification. The inventor finds out through a large number of experiments that the CREG expression is obviously reduced in a mouse vascular calcification model established by a method of injecting VitD 3. CREG heterozygous mice exacerbate vascular calcification caused by VitD 3; in contrast, CREG transgenic mice improved vascular calcification induced by VitD 3. The cytological level shows that the reduction of CREG expression can aggravate the calcification of mouse vascular smooth muscle cells caused by phosphate; conversely, overexpression of CREG inhibited pi-induced calcification of mouse VSMCs. The research provides new experimental basis and theoretical clues for deeply clarifying the regulation and control mechanism of the vascular calcification, and possibly provides new intervention targets for the prevention and treatment of vascular diseases concerned such as the vascular calcification and the like.
PURPOSE:To obtain an anti-RS virus agent having high safety by using rutin or its derivative as an active component. CONSTITUTION:The objective agent contains rutin or its derivative as an active component. Rutin is a compound separated from various plants such as buckwheat, effective for reinforcing capillary vessel and known as a vasodilator for preventing cerebral apoplexy, hypertension, pulmonary hemorrhage, peliosis, retinal apoplexy, etc. The rutin derivative is e.g. a compound produced by methoxylating a part or total of the hydroxyl group of the aglycon part of rutin and a compound produced by the sugar-transfer of a glycoside part of rutin. The rutin-containing plant is e.g. phagopilam, aesculentum, Nicotiana tabacum and viola.
There have been reports of adverse events occurring upon discontinuation of serotonergic antidepressants, particularly when discontinuation is abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. 

Monitor patients for these symptoms when discontinuing levomilnacipran. Reduce the dose gradually whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, consider resuming the previously prescribed dose. Subsequently, the dose may be decreased, but at a more gradual rate [see Dosage and Administration (2.4)].
FIELD: medicine, oncology. SUBSTANCE: method involves hydrolysis and extraction of lignin-containing raw in an alkaline medium, oxidation with oxygen-containing gas, separation of the liquid phase, its acidification, separation of obtained precipitate, its washing out up to the neutral pH value, drying, mixing with pyrophosphate, dissolving in water at heating and addition of NaCl to obtain the end product. Method involves also addition of HCl to the end product to obtain the neutral pH value. The precipitate obtained by an alkaline hydrolysis and oxidation of lignin and pyrophosphate as measured for pyrophosphate ions are mixed at the ratio 25:17 by dry matter at precision 10% and dissolved in water. An antitumor agent has a product of an alkaline hydrolysis and oxidation of lignin, pyrophosphate, NaCl and water. It has additionally HCl at amount providing pH 7 at precision 10%. Components have the following ratio by mass at precision 10%: product of hydrolysis and oxidation of lignin 25; pyrophosphate as measured for pyrophosphate ions 17; NaCl 3 and water up to 1000. EFFECT: decreased painfulness of administration of an agent. 2 cl, 1 ex
G3P-01 will be administered orally as a powdered mixed with water. Treatment Period two dose will be 500mg of IP.
Research into vaccine hesitancy is a critical component of the public health enterprise, as rates of communicable diseases preventable by routine childhood immunization have been increasing in recent years. It is therefore important to estimate proportions of "never-vaccinators" in various subgroups of the population in order to successfully target interventions to improve childhood vaccination rates. However, due to privacy issues, it may be difficult to obtain individual patient data (IPD) needed to perform the appropriate time-to-event analyses: state-level immunization information services may only be willing to share aggregated data with researchers. We propose statistical methodology for the analysis of aggregated survival data that can accommodate a cured fraction based on a polynomial approximation of the mixture cure model log-likelihood function relying only on summary statistics. We study the performance of the method through simulation studies and apply it to a real-world data set from a study examining reminder/recall approaches to improve human papillomavirus (HPV) vaccination uptake. The proposed methods may be generalized for use when there is interest in fitting complex likelihood-based models but IPD is unavailable due to data privacy or other concerns.
The invention provides a proved prescription used for treating icteric yang-yellow hepatitis. Icteric infectious hepatitis is an acute infectious disease caused by viruses and is infected mainly through alimentary canals. During onset of icteric yang-yellow hepatitis, one normally has a fever, feels fatigue, does not want to eat anything, hates oily food and suffers from nausea and vomiting, abdominal distension and persistent dull pain in a hepatic region; the symptoms like strong tea-like urine and greyish white stool occur, and sclera (the white of the eye) and the skin become yellow in several days. Yang yellow has the symptoms of a yellow and bright color, thirst and dry stool. According to the invention, Artemisia capillaris Thunb is used as a main medicine, the main medicine and other accessory traditional Chinese medicines are decocted by using a herbal medicine decocting method so as to extract a decoction, and the decoction is orally taken after mutual dissolution of the medicines. The proved prescription used for treating icteric yang-yellow hepatitis is developed on the basis of years of repeated research, clinical healing of considerable cases of patients with icteric yang-yellow hepatitis and repeated practice, starts from yellow elimination and dieresis, can effectively activate hepatocyte cambiums, repair immunologic functions of the liver in time and substantially enhance resistance, realizes treatment based on nosogenesis, has no toxic and side effects, is capable of effectively controlling conditions of icteric yang-yellow hepatitis and eliminating complications after administration and has a unique treatment effect.
A purified antigenic surface protein of Anaplasma marginale has been identified, and is capable of inducing immune responses in ruminants which neutralizes virulent Anaplasma marginale. The antigenic surface protein has a molecular weight of about 105,000 daltons, and can be purified by an immunoaffinity chromatography process. The antigen has further utility in diagnostic tests for anaplasmosis. It can be synthesized by polypeptide procedures or by genetic engineering. DNA and amino acid sequences have been developed for the antigen according to this invention. The antigen is useful as a vaccine component for protecting mammals against infection by Anaplasma marginale and may be useful for rickettsial organisms other than Anaplasma marginale.
A course of therapy is three doses of NeoProfen administered intravenously (administration via an umbilical arterial line has not been evaluated). An initial dose of 10 mg per kilogram is followed by two doses of 5 mg per kilogram each, after 24 and 48 hours. All doses should be based on birth weight. If anuria or marked oliguria (urinary output <0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose of NeoProfen, no additional dosage should be given until laboratory studies indicate that renal function has returned to normal. If the ductus arteriosus closes or is significantly reduced in size after completion of the first course of NeoProfen, no further doses are necessary. If during continued medical management the ductus arteriosus fails to close or reopens, then a second course of NeoProfen, alternative pharmacological therapy, or surgery may be necessary.
The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
Immediately following the "on NCPAP" condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed "off NCPAP" swallows.
E6 and E7 oncogenes are pivotal in the carcinogenic transformation in HPV infections and efficient diagnostic methods can ensure the detection and differentiation of HPV genotype. This study describes the development and validation of an electrochemical, label-free genosensor coupled with a microfluidic system for detecting the E6 and E7 oncogenes in cervical scraping samples. The nanostructuring employed was based on a cysteine and graphene quantum dots layer that provides functional groups, surface area, and interesting electrochemical properties. Biorecognition tests with cervical scraping samples showed differentiation in the voltammetric response. Low-risk HPV exhibited a lower biorecognition response, reflected in ΔI% values of 82.33 % ± 0.29 for HPV06 and 80.65 % ± 0.68 for HPV11 at a dilution of 1:100. Meanwhile, high-risk, HPV16 and HPV18, demonstrated ΔI% values of 96.65 % ± 1.27 and 93 % ± 0.026, respectively, at the same dilution. Therefore, the biorecognition intensity followed the order: HPV16 >HPV18 >HPV06 >HPV11. The limit of detection and the limit of quantification of E6E7 microfluidic LOC-Genosensor was 26 fM, and 79.6 fM. Consequently, the E6E7 biosensor is a valuable alternative for clinical HPV diagnosis, capable of detecting the potential for oncogenic progression even in the early stages of infection.
PURPOSE: Neurogenic lower urinary tract dysfunction (NLUTD) is common in patients with neurological lesions in the central nervous system (CNS). Medical treatment usually cannot adequately relieve NLUTD. This study reported the real-life treatment outcome of botulinum toxin A (BoNT-A) for overactive bladders (OAB) and voiding dysfunction in patients with CNS lesions.
METHODS: We retrospectively analyzed the first-time treatment outcome of 74 patients who received detrusor 100 U BoNT-A for OAB and 45 patients who received a urethral sphincter 100 U BoNT-A injection for voiding dysfunction. The treatment outcome, therapeutic duration, and adverse events (AE) after BoNT-A were compared among different CNS lesions and among patients with different urodynamic characteristics.
RESULTS: The study included 74 patients receiving detrusor injections for OAB (36 with cerebrovascular accidents, 13 with Parkinson's disease, and 25 with dementia) and 45 patients receiving a urethral sphincter injection for voiding dysfunction (26 with cerebrovascular accidents, 7 with Parkinson's disease, and 12 with dementia). After detrusor BoNT-A treatment, urinary continence was achieved in 28.4% of patients with neurogenic OAB, postoperative difficult urination in 59.5%, acute urinary retention (AUR) in 9.5%, and urinary tract infection (UTI) in 14.9%, with a therapeutic duration of 6.43 months. There were no differences among subgroups or between patients with detrusor overactivity (DO) and DO with detrusor underactivity (DU) in terms of treatment outcomes and AEs. The improvement rate of urethral sphincter BoNT-A injections was 75.6% without any difference among subgroups. After treatment, 24.4% of the patients had exacerbated urinary incontinence, 33.3% had persistent difficult urination, and 15.6% had UTI. Patients with dementia had higher rates of difficult urination and UTI, higher postvoid residual volume, and a shorter therapeutic duration. Patients with DU and those without urethral sphincter dyssynergia had less favorable outcomes after their urethral sphincter BoNT-A injection.
CONCLUSIONS: The therapeutic efficacy of detrusor BoNT-A injection for OAB due to CNS lesions is limited, with high rates of difficult urination, AUR, and UTI. Although urethral sphincter BoNT-A injection is effective in treating voiding dysfunction; however, exacerbated urinary incontinence and persistent difficult urination remain a problem, particularly in patients with dementia.
Participants will be moved into this arm if they are initially randomized into the intervention arm, but they receive the TIPPI-R intervention outside of the window dictated in the protocol. According to the protocol, consented participants should receive the interventions within 2 weeks of consent. If they do not, the TIPPI-R intervention will still be delivered and the participant will be moved to this arm of the study.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes a medicinal form for relief of nasal congestive symptoms. Agent consists of two discrete zones: the first zone comprises sympathomimetic-base composition and provides its prolonged continuous release and the second zone comprises antihistamine composition for immediate release of its active component. Invention provides acceptable bioavailability of each active components, stability in storage and acceptable physical strength. EFFECT: expanded assortment of agents of indicated designation, valuable properties of composition. 17 cl, 11 tbl, 1 ex
BACKGROUND: The CD16brightCD62Ldim neutrophil subtype is a recently identified neutrophil subtype. The aim of this study was to evaluate changes of peripheral blood CD16brightCD62Ldim neutrophils in patients with sepsis-associated ARDS.
METHODS: We prospectively recruited adult patients with sepsis-associated ARDS in the intensive care unit (ICU). Patient demographic data, medical history information, and laboratory data were collected within 48 hours of enrollment, and flow cytometry was applied to analyze the CD16brightCD62Ldim neutrophil subtype in the patients' peripheral blood. Multifactor COX regression models were used to analyze factors affecting prognosis, and Spearman correlation coefficients were used to analyze clinical and laboratory indicators affecting complications of infection.
RESULTS: Of the 40 patients, 9 patients died by the 28-day follow-up, indicating a mortality rate of 22.5%. Patients in the nonsurvival group had higher CD16brightCD62Ldim neutrophil levels. Patients with sepsis-associated ARDS who had a baseline proportion of CD16brightCD62Ldim neutrophil subtypes to total neutrophils in peripheral blood >3.73% had significantly higher 28-day mortality, while patients with CD16brightCD62Ldim neutrophil subtypes counts >2.62×109/L were also associated with significantly higher 28-day mortality. The percentage of the CD16brightCD62Ldim neutrophil subtype (HR=5.305, 95% CI 1.986-14.165, p=0.001) and IL-8 (HR=3.852, 95% CI 1.561-9.508, p=0.003) were independent risk factors for the development of infectious complications in patients with sepsis-related ARDS. The percentage of CD16brightCD62Ldim neutrophil subtypes predicted an AUC of 0.806 (95% CI 0.147-0.964, P=0.003) for the development of infectious complications, and 0.742 (95% CI 0.589-0.895, P=0.029) for the prediction of death within 28 days.
CONCLUSION: We identified for the first time that CD16brightCD62Ldim neutrophils are elevated in patients with sepsis-associated ARDS and are associated with infectious complications and poor prognosis. The percentage of CD16brightCD62Ldim neutrophil subtypes may serve as a predictor of the development of infectious complications in patients with ARDS.